0001645113-20-000134.txt : 20200911
0001645113-20-000134.hdr.sgml : 20200911
20200911161546
ACCESSION NUMBER: 0001645113-20-000134
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200909
FILED AS OF DATE: 20200911
DATE AS OF CHANGE: 20200911
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEUNG GABRIEL
CENTRAL INDEX KEY: 0001236183
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37565
FILM NUMBER: 201171104
MAIL ADDRESS:
STREET 1: C/O PERNIX THERAPEUTICS HOLDINGS, INC.
STREET 2: 10 NORTH PARK PLACE, SUITE 201
CITY: MORRISTOWN
STATE: NJ
ZIP: 07960
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NovoCure Ltd
CENTRAL INDEX KEY: 0001645113
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: NO. 4 THE FORUM
STREET 2: GRENVILLE STREET
CITY: ST. HELIER
STATE: Y9
ZIP: JE2 4UF
BUSINESS PHONE: 44 (0)15 3475 6700
MAIL ADDRESS:
STREET 1: NO. 4 THE FORUM
STREET 2: GRENVILLE STREET
CITY: ST. HELIER
STATE: Y9
ZIP: JE2 4UF
FORMER COMPANY:
FORMER CONFORMED NAME: Novocure Ltd
DATE OF NAME CHANGE: 20150615
4
1
wf-form4_159985533001922.xml
FORM 4
X0306
4
2020-09-09
0
0001645113
NovoCure Ltd
NVCR
0001236183
LEUNG GABRIEL
C/O NOVOCURE INC.
20 VALLEY STREAM PARKWAY, SUITE 300
MALVERN
PA
19355
1
0
0
0
Ordinary Shares
2020-09-09
4
M
0
9114
7.03
A
81159
D
Ordinary Shares
2020-09-09
4
S
0
9014
85.388
D
72145
D
Ordinary Shares
2020-09-09
4
S
0
100
86.06
D
72045
D
Ordinary Shares
2020-09-10
4
M
0
10000
7.48
A
82045
D
Ordinary Shares
2020-09-10
4
S
0
10000
90
D
72045
D
Options to Buy Ordinary Shares
7.03
2020-09-09
4
M
0
9114
0
D
2023-02-19
Ordinary Shares
9114.0
0
D
Options to Buy Ordinary Shares
7.48
2020-09-10
4
M
0
10000
0
D
2024-02-25
Ordinary Shares
10000.0
12173
D
On September 9, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung, Mr. Leung sold 9,014 shares in multiple trades at prices ranging from $85.00 to $85.92. The price reported above reflects the weighted average sale price. Mr. Leung hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung.
Fully vested as of the date hereof.
By: /s/ Steven Robbins, Attorney in Fact for Kinyip Gabriel Leung
2020-09-11